We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Measuring response in a post-RECIST world: from black and white to shades of grey.
- Authors
Michaelis, Laura C.; Ratain, Mark J.
- Abstract
The unprecedented pace of therapeutic development in oncology has created a climate in which the traditional methods of evaluating agent activity might no longer be adequate. How is the field transitioning to new endpoints in early drug development and what are the difficulties in this transition? Here, we will explore the historical context for the current criteria for tumour response evaluation and some of the pitfalls in using these standards when testing newer anticancer agents for activity. We will argue that the current drug development environment dictates different outcome measurements and therefore more imaginative and rigorous early-phase trial designs.
- Subjects
TUMORS; ANTINEOPLASTIC agents; ONCOLOGY; DRUG development; CLINICAL drug trials; CLINICAL trials; EXPERIMENTAL design; TREATMENT effectiveness; DISEASE progression
- Publication
Nature Reviews Cancer, 2006, Vol 6, Issue 5, p409
- ISSN
1474-175X
- Publication type
review
- DOI
10.1038/nrc1883